心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2022 NHS 临床指南：冠心病和中风，一级和二级预防指南（胆固醇）（181）

2022-05-11 NHS 大格拉斯哥和克莱德 nhsggc官网

冠心病中风一级预防二级预防

指南旨在帮助医疗保健专业人员选择针对疾病的治疗方法。

中文标题：

2022 NHS 临床指南：冠心病和中风，一级和二级预防指南（胆固醇）（181）

英文标题：

Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guideline (Cholesterol) (181)

发布机构：

NHS 大格拉斯哥和克莱德

发布日期：

2022-05-11

简要介绍：

高危患者(预计10年内心血管事件发生率为20%或以上)应接受他汀类药物治疗，对所有40岁的糖尿病患者，以及年龄<40岁的糖尿病患者>20年或有靶器官损害的患者，不进行额外的风险评估。≥。阿司匹林不是糖尿病患者的常规适应症，因为他们不知道有动脉粥样硬化。

治疗慢性肾脏疾病(CKD 3-5)患者，无需额外的风险评估。没有证据表明在已经进行透析的患者中开始使用他汀类药物对心血管有益。

相关资料下载：
[AttachmentFileName(sort=1, fileName=chd-stroke.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9e4b51c0025e136c, title=2022 NHS 临床指南：冠心病和中风，一级和二级预防指南（胆固醇）（181）, enTitle=Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guideline (Cholesterol) (181), guiderFrom=nhsggc官网, authorId=0, author=, summary=指南旨在帮助医疗保健专业人员选择针对疾病的治疗方法。 , cover=https://img.medsci.cn/20220806/1659793063256_1608702.png, journalId=0, articlesId=null, associationId=3040, associationName=NHS 大格拉斯哥和克莱德 , associationIntro=NHS 大格拉斯哥和克莱德 (NHSGGC), copyright=0, guiderPublishedTime=Wed May 11 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p>高危患者(预计10年内心血管事件发生率为20%或以上)应接受他汀类药物治疗，对所有40岁的糖尿病患者，以及年龄&lt;40岁的糖尿病患者&gt;20年或有靶器官损害的患者，不进行额外的风险评估。&ge;。阿司匹林不是糖尿病患者的常规适应症，因为他们不知道有动脉粥样硬化。</p> <p>治疗慢性肾脏疾病(CKD 3-5)患者，无需额外的风险评估。没有证据表明在已经进行透析的患者中开始使用他汀类药物对心血管有益。</p>, tagList=[TagDto(tagId=703, tagName=冠心病), TagDto(tagId=1413, tagName=中风), TagDto(tagId=2930, tagName=一级预防), TagDto(tagId=3552, tagName=二级预防)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3947, appHits=278, showAppHits=0, pcHits=667, showPcHits=3662, likes=1, shares=38, comments=4, approvalStatus=1, publishedTime=Thu Aug 11 21:30:00 CST 2022, publishedTimeString=2022-05-11, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Sat Aug 06 21:39:32 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Fri Jan 05 23:17:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=chd-stroke.pdf)])
chd-stroke.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2094334, encodeId=7bad2094334ce, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1142952884, createdName=tengjx, createdTime=Tue Oct 18 00:02:15 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238185, encodeId=b8271238185f8, content=很好<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e6469401, createdName=ms7000000458032466, createdTime=Fri Aug 12 00:17:57 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238136, encodeId=ba9e123813633, content=，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Thu Aug 11 21:41:48 CST 2022, time=2022-08-11, status=1, ipAttribution=)]
    2022-10-18 tengjx

    棒

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2094334, encodeId=7bad2094334ce, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1142952884, createdName=tengjx, createdTime=Tue Oct 18 00:02:15 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238185, encodeId=b8271238185f8, content=很好<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e6469401, createdName=ms7000000458032466, createdTime=Fri Aug 12 00:17:57 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238136, encodeId=ba9e123813633, content=，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Thu Aug 11 21:41:48 CST 2022, time=2022-08-11, status=1, ipAttribution=)]
    2022-08-12 ms7000000458032466

    很好#肿瘤#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2094334, encodeId=7bad2094334ce, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1142952884, createdName=tengjx, createdTime=Tue Oct 18 00:02:15 CST 2022, time=2022-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238185, encodeId=b8271238185f8, content=很好<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e6469401, createdName=ms7000000458032466, createdTime=Fri Aug 12 00:17:57 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238136, encodeId=ba9e123813633, content=，, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKgrnf67D3ddbalXADDrBnicULYYIn4tjz2jTiagbqHqFntDkYCVkE7WnVnz26n6XXUk4hTmFR8iczDQ/132, createdBy=4e9f5263713, createdName=cyfguvgi, createdTime=Thu Aug 11 21:41:48 CST 2022, time=2022-08-11, status=1, ipAttribution=)]
    2022-08-11 cyfguvgi

    ，

    0

相关指南

高血压合并冠心病患者血压管理中国专家共识

中国医疗保健国际交流促进会 · 2022-03-15

麝香保心丸治疗冠心病专家共识

中国医师协会中西医结合医师分会心血管病专业委员会 · 2022-05-10

体外心脏震波治疗冠心病中国专家共识（2022版）

中国医师协会心血管内科医师分会(CCCP,Chinese College of Cardiovascular Physicians) · 2022-02-25

最新药物涂层球囊专家共识解读

暂未更新 · 2021-11-15

稳定性冠心病基层合理用药指南

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2021-04-06

冠心病合理用药指南(第2版)

国家卫生计生委合理用药专家委员会 · 2018-03-01